1. Home
  2. YAAS vs CABA Comparison

YAAS vs CABA Comparison

Compare YAAS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YAAS
  • CABA
  • Stock Information
  • Founded
  • YAAS 2018
  • CABA 2017
  • Country
  • YAAS China
  • CABA United States
  • Employees
  • YAAS N/A
  • CABA N/A
  • Industry
  • YAAS Computer Software: Prepackaged Software
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • YAAS Technology
  • CABA Health Care
  • Exchange
  • YAAS Nasdaq
  • CABA Nasdaq
  • Market Cap
  • YAAS 127.2M
  • CABA 118.8M
  • IPO Year
  • YAAS 2024
  • CABA 2019
  • Fundamental
  • Price
  • YAAS $2.62
  • CABA $2.06
  • Analyst Decision
  • YAAS
  • CABA Strong Buy
  • Analyst Count
  • YAAS 0
  • CABA 8
  • Target Price
  • YAAS N/A
  • CABA $26.13
  • AVG Volume (30 Days)
  • YAAS 89.7K
  • CABA 1.4M
  • Earning Date
  • YAAS 01-01-0001
  • CABA 03-20-2025
  • Dividend Yield
  • YAAS N/A
  • CABA N/A
  • EPS Growth
  • YAAS N/A
  • CABA N/A
  • EPS
  • YAAS N/A
  • CABA N/A
  • Revenue
  • YAAS $521,240.00
  • CABA N/A
  • Revenue This Year
  • YAAS N/A
  • CABA N/A
  • Revenue Next Year
  • YAAS N/A
  • CABA N/A
  • P/E Ratio
  • YAAS N/A
  • CABA N/A
  • Revenue Growth
  • YAAS N/A
  • CABA N/A
  • 52 Week Low
  • YAAS $2.01
  • CABA $1.76
  • 52 Week High
  • YAAS $4.50
  • CABA $24.85
  • Technical
  • Relative Strength Index (RSI)
  • YAAS N/A
  • CABA 38.28
  • Support Level
  • YAAS N/A
  • CABA $2.03
  • Resistance Level
  • YAAS N/A
  • CABA $2.90
  • Average True Range (ATR)
  • YAAS 0.00
  • CABA 0.24
  • MACD
  • YAAS 0.00
  • CABA -0.04
  • Stochastic Oscillator
  • YAAS 0.00
  • CABA 4.00

About YAAS Youxin Technology Ltd Class A Ordinary shares

Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: